Grace Therapeutics (NASDAQ:GRCE) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Grace Therapeutics (NASDAQ:GRCE) announced its earnings results on Thursday. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01, Zacks reports.

Grace Therapeutics Price Performance

GRCE opened at $3.48 on Friday. Grace Therapeutics has a fifty-two week low of $2.13 and a fifty-two week high of $4.97. The business’s 50-day moving average price is $3.73. The stock has a market cap of $35.29 million, a P/E ratio of -3.45 and a beta of 1.36.

Grace Therapeutics Company Profile

Grace Therapeutics Inc is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc, formerly known as Acasti Pharma Inc, is based in Princeton, New Jersey.